Gsa Capital Partners LLP Intra Cellular Therapies, Inc. Transaction History

Gsa Capital Partners LLP

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$64.76 - $79.84 $20,399 - $25,149	315 Added 9.39%	3,668 $251,000
Q1 2024 May 03, 2024	BUY	$64.37 - $75.65 $215,832 - $253,654	3,353 New	3,353 $232,000
Q3 2023 Nov 15, 2023	BUY	$52.09 - $64.1 $71,415 - $87,881	1,371 Added 20.31%	8,122 $423,000
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $369,077 - $448,536	6,751 New	6,751 $427,000
Q4 2022 Feb 13, 2023	BUY	$44.07 - $54.45 $241,944 - $298,930	5,490 New	5,490 $291,000
Q2 2021 Aug 05, 2021	SELL	$29.3 - $44.5 $270,028 - $410,112	-9,216 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$30.8 - $39.51 $283,852 - $364,124	9,216 New	9,216 $313,000
Q2 2020 Aug 11, 2020	SELL	$14.35 - $26.64 $201,517 - $374,105	-14,043 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$12.31 - $33.12 $172,869 - $465,104	14,043 New	14,043 $216,000
Q4 2019 Feb 12, 2020	SELL	$7.26 - $38.49 $303,634 - $1.61 Million	-41,823 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$7.47 - $14.03 $312,417 - $586,776	41,823 New	41,823 $312,000
Q1 2019 May 15, 2019	SELL	$10.9 - $14.09 $135,694 - $175,406	-12,449 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$10.36 - $20.96 $128,971 - $260,931	12,449 New	12,449 $142,000
Q3 2018 Nov 13, 2018	SELL	$17.77 - $22.9 $863,515 - $1.11 Million	-48,594 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$17.33 - $23.4 $76,251 - $102,960	4,400 Added 9.96%	48,594 $859,000
Q1 2018 May 11, 2018	SELL	$15.16 - $25.49 $1.01 Million - $1.71 Million	-66,906 Reduced 60.22%	44,194 $930,000
Q4 2017 Feb 14, 2018	BUY	$14.27 - $16.79 $1.59 Million - $1.87 Million	111,100	111,100 $1.61 Million

378

84.7M

319K

143K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $7.92B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.